IDG Capital

What IDG Capital does

IDG Capital is a privately held global venture capital and private equity firm founded in Boston in 1993 and headquartered in Hong Kong, with twelve offices across Asia Pacific (Beijing, Shanghai, Shenzhen, Guangzhou, Hong Kong, Singapore, Seoul), Europe (Barcelona), the Americas (New York, Boston), the Middle East (Muscat), and the Cayman Islands for fund structuring. The firm operates a multi-strategy investment platform spanning the full company lifecycle — Venture Capital, Growth Capital, Buyout, Secondary Markets, and Public Markets — and is staffed by 300+ professionals of whom 40% are investment professionals. IDG Capital has backed 1,800+ portfolio companies across 10+ markets and recorded 600+ exits.

Revenue is generated from three streams: investment management fees on committed capital under management, carried interest from successful exits, and realized gains from portfolio liquidity events. IDG Capital's portfolio spans frontier AI labs (DeepSeek, Moonshot AI, MiniMax), humanoid robotics (ROBOTERA), brain-computer interfaces (BrainCo, Zhiran Medical), semiconductors (Sunrise, Anhui Shenji / Nio GeniTech), fintech and stablecoin infrastructure (Circle, OPay, PhotonPay, Transak), biotech (D3 Bio), advanced energy (Dongsheng Fusion, Ruien New Energy), and consumer brands (Yoplait China, Lakrids by Johan Bülow). The firm holds a controlling stake in Yoplait China's dairy business, acquired for RMB 1.8 billion in December 2025, and operates i-Incubator Healthcare, a wholly owned Shanghai-based drug innovation incubator established in 2024.

Distribution to founders occurs through IDG Capital's official website, LinkedIn, X, industry events, and an extensive warm-introduction network derived from its 1,800+ portfolio companies. Recent strategic activity underscores a sharpened focus on China's frontier-tech stack: IDG Capital led Moonshot AI's $500 million Series C at a $4.3 billion valuation, committed RMB 3 billion to DeepSeek's first external funding round exceeding RMB 50 billion, participated in ROBOTERA's USD 200+ million round, and served as a cornerstone investor in MiniMax's Hong Kong IPO. The firm has also been shortlisted alongside EQT for the next round of bidding on Swiss contract drugmaker PolyPeptide, signaling continued appetite for cross-border life-sciences platforms.

Name

IDG Capital

Legal name

IDG Capital

Website

https://cn.idgcapital.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

IDG Capital is a Hong Kong-headquartered global venture capital and private equity firm founded in 1993, operating multi-strategy funds across venture, growth, buyout, secondary, and public markets with 1,800+ portfolio companies and 600+ exits.

Ownership category

akta.pro rank

Product category

Private Equity and Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

Keywords

• Venture capital
• Private equity
• Growth capital
• Buyout transactions
• Secondary markets

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Management Fees: VC/PE firms typically charge management fees on committed capital under management, generating steady revenue stream regardless of investment performance.
2. Carried Interest (Performance Fees): Profit participation from successful portfolio company exits, representing the primary upside for the firm and its investors when investments perform well.
3. Realized Gains from Exits: Revenue generated from exits through IPOs, acquisitions, and secondary transactions. The firm has achieved 600+ exits across multiple exit pathways.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

IDG Capital is a global venture capital and private equity firm that deploys capital across the full business-building and public company expansion lifecycle through five core investment vehicles: Venture Capital (early-stage), Growth Capital (long-term strategic partnerships), Buyout (complex transactions and corporate mergers), Secondary Markets (liquidity for private equity stakes), and Public Markets (listed equities and hybrid assets). The firm also supports portfolio companies with strategic guidance, ecosystem connections, talent recruitment, and geographic expansion assistance.

Product overview

IDG Capital offers a unified investment platform spanning the full business-building and public company expansion lifecycle through five core investment services: Venture Capital for early-stage companies, Growth Capital for strategic partnerships, Buyout for complex transactions, Secondary Markets for liquidity solutions, and Public Markets for listed equities. Featured portfolio companies include Yoplait China (premium chilled dairy), Circle (global stablecoin payments/USDC issuer), and i-Incubator Healthcare (drug innovation incubator).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 600+ successful exits across multiple pathways
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MicrosoftminorStrategic or Co-development Partner · 18 June 2026Microsoft is reportedly evaluating DeepSeek for its Copilot product, citing lower costs compared to OpenAI and Anthropic. IDG Capital is an investor in DeepSeek.

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Sequoia Capital China (HongShan): One of IDG's most frequent co-investors in marquee China tech deals (Moonshot AI, D3 Bio, Zhiran Medical, Dongsheng Fusion). HongShan is a China-focused venture and growth firm with comparable scale, sector coverage, and stage mix, competing for the same founder relationships and deals.
• Hillhouse Investment: Asia-focused multi-strategy investor co-investing with IDG across BrainCo, ROBOTERA, Dongsheng Fusion, and other major China deals. Hillhouse runs venture, growth, and public-equity strategies across consumer, healthcare, and tech — directly comparable to IDG's full-lifecycle platform.
• Temasek: Singapore sovereign-backed investor co-investing alongside IDG in D3 Bio and other China deals. Temasek operates across venture, growth, and public-equity stages globally and competes with IDG for large-ticket, late-stage China and Southeast Asia opportunities.
• Legend Capital (Lenovo Capital): China-focused VC and growth investor that co-invested with IDG in Zhiran Medical. Competes directly for early- and growth-stage deals in Chinese tech, healthcare, and consumer sectors.
• SAIF Partners: Asia-focused growth and venture firm investing in China tech and consumer; historically a comparable mid-to-large China VC peer with similar stage focus and sector coverage as IDG.

Broad incumbents

• Warburg Pincus: Global growth-equity firm with deep China presence across technology, healthcare, and consumer — overlapping with IDG's growth and buyout strategies at the larger end of the deal-size spectrum.
• KKR & Co. Global alternatives manager running venture, growth, buyout, and credit strategies across Asia. Comparable in scale and multi-strategy breadth to IDG's platform, though more buyout-tilted and broader geographically.
• Bain Capital: Global alternatives platform with venture, growth, buyout, and credit strategies, including Bain Capital Asia and Bain Capital Ventures. Competes with IDG for growth and buyout deals in Asia and the U.S.
• Carlyle Group: Global alternatives investor with venture, growth, and buyout funds operating across Asia. Comparable in multi-strategy platform breadth and cross-border deployment to IDG, though larger average deal sizes.

Emerging players

• Source Code Capital: China tech-focused VC competing with IDG in consumer internet and enterprise software. Smaller and earlier-stage than IDG but overlapping in TMT deal flow within China.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IDGCapital
• LinkedInlinkedin.com/company/idgvc
• Facebookfacebook.com/IDGCapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments1643 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDG Capital